Description
Kogelox IV Levofloxacin 750mg/150ml is a broad-spectrum intravenous antibiotic infusion used to treat a variety of bacterial infections. Manufactured by ZAQA, this infusion contains 750 mg of Levofloxacin hemihydrate per 150 ml and is indicated for patients who are unable to take oral medications.
Key Features:
-
Active Ingredient: Levofloxacin hemihydrate 750 mg
-
Formulation: Intravenous infusion (ready-to-use)
-
Volume: 150 ml per vial
-
Manufacturer: ZAQA
-
Availability: Available in Bangladesh through various pharmaceutical suppliers
Indications:
Kogelox IV is used for the treatment of infections caused by susceptible microorganisms, including:
-
Respiratory tract infections (e.g., community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis)
-
Urinary tract infections (e.g., complicated and uncomplicated UTIs, acute pyelonephritis)
-
Skin and soft tissue infections
-
Intra-abdominal infections
-
Bone and joint infections
-
Prostatitis
Dosage and Administration:
-
Usual Dose: 750 mg once daily
-
Administration: Slow intravenous infusion
-
For 750 mg dose: Infuse over 90 minutes
-
-
Renal Impairment: Dosage adjustment may be necessary for patients with impaired renal function
Note: Always consult a healthcare professional for appropriate dosing and administration.
Contraindications:
-
Hypersensitivity to Levofloxacin, other quinolones, or any component of the formulation
-
Patients with a history of tendon disorders related to quinolone use
Warnings and Precautions:
-
Risk of tendonitis and tendon rupture
-
May cause central nervous system effects (e.g., seizures, tremors, confusion)
-
Potential for QT interval prolongation
-
Use with caution in patients with renal impairment
Side Effects:
Common side effects may include:
-
Nausea
-
Diarrhea
-
Headache
-
Dizziness
-
Insomnia
Serious side effects are rare but may include:
-
Tendon rupture
-
Seizures
-
Allergic reactions
Storage:
-
Store below 30°C
-
Protect from light
-
Keep out of reach of children
Reviews
There are no reviews yet.